OmniAb Inc (NASDAQ: OABI) is a biotechnology company that provides proprietary transgenic animal platforms and related discovery technologies to pharmaceutical and biotechnology partners for the discovery of therapeutic antibody candidates. The company makes money through license agreements with partners, collecting fees, milestones, and royalties as partnered programs advance through development and, ultimately, toward commercialization. OmniAb operates as an upstream discovery-platform licensor, sitting early in the drug development value chain rather than advancing its own drugs to market. Research and development is conducted at facilities in Emeryville, California, Durham, North Carolina, and Tucson, Arizona (as of the 10-K filed March 4, 2026). Matthew W. Foehr serves as President and Chief Executive Officer, and Kurt Gustafson serves as Executive Vice President, Finance and Chief Financial Officer, both as of March 4, 2026. The company has reported accumulated deficits and net losses through December 31, 2025, and has raised capital through an at-the-market equity facility and a private placement.

Revenue model

License agreements with pharmaceutical and biotechnology partners, generating upfront fees, development milestone payments, and royalties on any commercial sales of drugs discovered using the OmniAb platform. Revenue is contingent on partner program progression and product approvals.

Products and services

OmniAb technology platform, including transgenic animal systems: OmniRat, OmniChicken, OmniMouse (genetically modified to produce human-sequence antibodies); OmniFlic and OmniClic (fixed common light-chain rats and chickens for bispecific antibody discovery); OmniTaur (cow-inspired antibodies for challenging targets); OmnidAb (in vivo single-domain antibody discovery platform using human VH scaffold in a chicken host); OmniUltra (in vivo discovery platform for human antibody repertoires with cow-inspired ultralong CDRH3 domains, also enabling isolation of picobodies); OmniDeep (in silico AI and machine learning tools for therapeutic discovery).

Customers and end markets

Pharmaceutical and biotechnology companies that license the OmniAb platform to discover therapeutic antibody candidates. End markets are human therapeutics, with demand driven by partner pipelines and clinical program advancement.

Value-chain role

Upstream discovery-platform licensor. OmniAb provides the animal platforms, automation systems, and AI tools that partners use to identify and optimize antibody drug candidates. The company does not itself conduct clinical trials or commercialize drugs.

Geographic exposure

Research and development operations in Emeryville, California, Durham, North Carolina, and Tucson, Arizona. International data transfer obligations under GDPR indicate some operations or partnerships involving the European Economic Area, though specific revenue by geography is not disclosed in the excerpts.

Source: SEC 10-K, filed 2026-03-04

Industry: Services-Commercial Physical & Biological Research Peers: Akoya Biosciences, Inc. BioLife Solutions Inc Bionano Genomics Inc SomaLogic, Inc. Codexis Inc MaxCyte Inc NS Wind Down Co., Inc. Quanterix Corp Seer Inc Thermo Fisher Scientific Inc